
Releases
Anixa Biosciences Advances Ovarian Cancer Therapy to Highest Dose
The first patient has been treated in the fifth cohort of an ongoing Phase 1 clinical trial for recurrent ovarian cancer, marking the highest dose level tested to date. Conducted at Moffitt Cancer Center, the study evaluates a novel CAR-T therapy targeting the follicle-stimulating hormone receptor.


























